Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction

Chest

Volumn 143, Issue 6, 2013, Pages 1699-1708

  Han, Meilan K ^a   Bach, David S ^a   Hagan, Peter G ^a   Yow, Eric ^b   Flaherty, Kevin R ^a   Toews, Galen B ^a   Anstrom, Kevin J ^b   Martinez, Fernando J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; PLACEBO; SILDENAFIL;

6 MINUTE WALK DISTANCE; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXERCISE; FIBROSING ALVEOLITIS; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RIGHT VENTRICULAR SYSTOLIC DYSFUNCTION; RIGHT VENTRICULAR SYSTOLIC PRESSURE; SCORING SYSTEM; SHORT FORM 36; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; TREATMENT RESPONSE; UNITED STATES; VISUAL ANALOG SCALE;

EID: 84878556549     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1594     Document Type: Article

References (23)

1. Weitzenblum E, Ehrhart M, Rasaholinjanahary J, Hirth C. Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration. 1983;44(2):118-127.
2. Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007;132(3):998-1006.
3. Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-2157.
4. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360(9337):895-900.
5. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007;131(3):897-899.
6. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620-628.
7. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167(5):735-740.
8. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746-752.
9. Nadrous HF, Pellikka PA, Krowka MJ, et al. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest. 2005;128(suppl 6):616S-617S.
10. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidencebased treatment algorithm in pulmonary arterial hypertension . J Am Coll Cardiol. 2009;54(1)(suppl): S78-S84.
11. Han MK, Bach D, Hagan P, et al. Presence of right ventricular dysfunction modifies treatment response to sildenafil in the Step-IPF Trial. Am J Respir Crit Care Med. 2011;183: A5301.
12. Han MK, Bach D, Hagan P, et al. Presence of right ventricular dysfunction predicts dyspnea and quality of life improvements with sildenafil in IPF. Eur Respir J. 2011;38:3S.
13. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2004;170(4):360-365.
14. Boutou AK, Pitsiou GG, Trigonis I, et al. Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension . Respirology. 2011;16(3):451-458.
15. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183(9):1231-1237.
16. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010;104(2):296-304.
17. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.
18. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(1):75-81.
19. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92-99.
20. Ventetuolo CE, Kawut SM, Lederer DJ. Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis. Respiration. 2012;84(4):299-305.
21. Nathan SD. Pulmonary hypertension in interstitial lung disease . Int J Clin Pract Suppl. 2008;62(160):21-28.
22. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005;128(4):2393-2399.
23. Han MK, McLaughlin VV, Criner GJ, Martinez FJ. Pulmonary diseases and the heart. Circulation. 2007;116(25):2992-3005.